63 results about "Polymeric scaffold" patented technology

A braided polymeric scaffold, made at least in part from a bioresorbable material is deployed on a catheter that uses a push-pull mechanism to deploy the scaffold. A drug coating is disposed on the scaffold. A plurality of scaffold segments on a catheter is also disclosed.

A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L^D-D, the protein based recognition-molecule being connected to the polymeric carrier by L^P. Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L^D and L^P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

The present invention relates to a method for the surface modification of a polymeric scaffold for stem cell transplantation using a decellularized extracellular matrix. The method for the surface modification of the polymeric scaffold according to the present invention can embody a biomimetic surface environment that is effective for initial cell attachment, cell growth and differentiation of stem cells by modifying the surface of the polymeric scaffold using the decellularized extracellular matrix directly derived from specific tissue cells.

Somatic lung progenitor cell/polymer constructs are disclosed along with methods for isolating somatic lung progenitor cells from adult mammals, seeding the cells onto or into polymeric scaffolds and allowing the cells to differentiate and proliferate into functional lung tissue/polymer implants. A method for treating lung disease, disorders or injuries is also disclosed.

Three-dimensional porous biodegradable and biocompatible, polymeric scaffolds for tissue engineering are prepared by a method involving effervescing of an effervescent salt in a gel to result in a porous structure. A polymer is dissolved in an organic solvent to prepare a polymer solution of high viscosity. Optionally, the polymer solution is mixed with an organic solvent that does not dissolve the polymer to concentrate the solution. An effervescent salt is homogeneously mixed with the polymer solution to give a polymer/salt/organic solvent mixed gel. The organic solvent is removed from the mixed gel to produce an organic solvent-free polymer/salt gel slurry. The gel slurry is submerged in a hot aqueous solution or acidic solution to cause the salt to effervesce at room temperature to form a porous three-dimensional polymeric structure. The polymeric structure is washed with distilled water and freeze-dried to yield a scaffold that is suitable for cell or tissue culture. Pore size and porosity of the scaffold can be easily controlled by controlling the size and amount of the effervescent salt and concentration of the acidic solution.

The present invention features nanohybrid drug delivery composition which combines both passive and active targeting for the prevention and treatment of disease. The composition is shell-encapsulated multivalent polymeric scaffold with a therapeutic agent and targeting agent attached thereto.

In one aspect, the present invention relates to a layered structure usable in a strain sensor. In one embodiment, the layered structure has a substrate with a first surface and an opposite, second surface defining a body portion therebetween; and a film of carbon nanotubes deposited on the first surface of the substrate, wherein the film of carbon nanotubes is conductive and characterized with an electrical resistance. In one embodiment, the carbon nanotubes are aligned in a preferential direction. In one embodiment, the carbon nanotubes are formed in a yarn such that any mechanical stress increases their electrical response. In one embodiment, the carbon nanotubes are incorporated into a polymeric scaffold that is attached to the surface of the substrate. In one embodiment, the surfaces of the carbon nanotubes are functionalized such that its electrical conductivity is increased.

Cartilage has been constructed using biodegradable electrospun polymeric scaffolds seeded with chondrocytes or adult mesenchymal stem cells. More particularly engineered cartilage has been prepared where the cartilage has a biodegradable and biocompatible nanofibrous polymer support prepared by electrospinning and a plurality of chondocytes or mesenchymal stem cells dispersed in the pores of the support. The tissue engineered cartilages of the invention possess compressive strength properties similar to natural cartilage. Methods of preparing engineered tissues, including tissue engineered cartilages, are provided in which an electrospun nanofibrous polymer support is provided, the support is treated with a cell solution and the polymer-cell mixture cultured in a rotating bioreactor to generate the cartilage. The invention provides for the use of the tissue engineered cartilages in the treatment of cartilage degenerative diseases, reconstructive surgery, and cosmetic surgery.

The present invention provides a polymeric scaffold containing an antibacterial photoactive drug and optionally comprising seeded cells such as stem cells. The invention also includes methods of using the scaffold for tissue regeneration, prevention or reduction of infection whilst tissue regeneration occurs, methods for improving graft or implant survival, promoting scaffold integration and tissue repair and wound healing.

This invention relates to a polymeric pharmaceutical dosage form for the delivery, in use, of at least one pharmaceutical composition in a rate-modulated and site-specific manner. The dosage form comprises a biodegradable, polymeric, scaffold incorporating loaded with at least one active pharmaceutical ingredient (API). The polymer or polymers making up the scaffold degrade in a human or animal body in response to or in the absence of specific biological stimuli and, on degradation, release the API or APIs in an area where said stimuli are encountered. Preferably the polymeric scaffold is formed from poly (D1L-lactide) (PLA) and polymethacrylate (Eudragit S100/ES100) polymers.

A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders, such as cancer in a subject having low HER2 expression with the conjugates or their compositions are also described.

A tubulysin compound conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L^D-D, the protein based recognition-molecule being connected to the polymeric carrier by L^P. Each occurrence of D is independently a tubulysin compound having a molecular weight≦5 kDa. L^D and L^P are distinct linkers connecting the tubulysin compound and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-tubulysin compound-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

Post deployment radial force recovery of biodegradable scaffolds are described where a high molecular weight polymer may be formed into a high molecular weight scaffold by solution casting into a tubular substrate such that the scaffold retains its mechanical properties through processing. The tubular substrate is laser cut and subsequently crimped onto a catheter for deployment into a body lumen. The polymeric scaffold may retain its mechanical properties and result in increased radial strength post-deployment in a saline environment, e.g., within a body lumen. This scaffold enhancement may be attributable at least in part to entanglement of high molecular weight polymer chains as one factor that effects radial force recovery and also to the design or geometry of the scaffold as another factor that effects radial force recovery after deployment.

A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.

A gingival attachment device associated with an endosseous implant, which comprises a cervically located component of a dental implant coated on a gingival facing surface thereof with a biocompatible and non-degradable polymeric scaffold, to which epithelial and connective tissue cells of the gingiva are attachable. The polymeric scaffold may be polyvinylpyrronidole mixed with butyl-methylmethacrylate, silk fibroin fibrous protein polymer mixed with chitosan or with derivatives of chitosan, and polyHEMA and may be coated on all gingival facing surfaces of the cervically located component.

A polymerizable unit that yields an electrochemically responsive polymer (advantageously pyrrole) is anchored by polymerization within a polycaprolactone matrix to form an electroactive scaffold upon which cells can be cultured and in which the micro- and nano-topological features of the polycaprolactone matrix are preserved. A scaffold manufactured in accordance with the preferred embodiment can support Schwann cells, which produce nerve growth factor when electrically stimulated. Nerve growth factor has been demonstrated to promote the regeneration of nerve tissue. By implanting the scaffold on which Schwann cells have been cultured into damaged nerve tissue and applying a voltage across the scaffold, nerve growth factor is produced, thereby promoting repair of the damaged nerve tissue.